DEL Technology Integrating C4T’s Cereblon Library Can Rapidly Advance Projects Into Hit-To-Lead Stage

DEL技术整合C4T的Cereblon文库可快速推动项目进入从命中到先导阶段

WATERTOWN, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today highlighted its novel DNA-encoded library (DEL) that leverages C4T’s large library of cereblon-binding ligands and screening capabilities in a presentation at the 9.

马萨诸塞州沃特敦，2026年10月29日（环球电讯社）——专注于推进靶向蛋白降解（TPD）科学的临床阶段生物制药公司C4 Therapeutics, Inc.（C4T）（纳斯达克股票代码：CCCC）今日在一次演讲中重点介绍了其新型DNA编码库（DEL），该库利用了C4T庞大的cereblon结合配体库及其筛选能力。

th

泰国

Annual Targeted Protein Degradation Summit in Boston titled “Target-First Discovery of Molecular Glue Degraders Using DNA-Encoded Libraries.”

在波士顿举行的年度靶向蛋白降解峰会，题为“利用DNA编码库进行分子胶降解剂的靶点优先发现”。

“Our new DEL capability captures both our strong track record of investing in cereblon and driving innovation across targeted protein degradation science to create a differentiated engine for generating new drug discovery opportunities,” said Scott Boyle, chief business officer of C4 Therapeutics. “To date, this new technology has shown it can deliver attractive hits against high-value targets within four months and further enhances the speed and precision of our discovery efforts.

C4 Therapeutics 首席商务官 Scott Boyle 表示：“我们全新的 DNA 编码库（DEL）能力，既彰显了我们在大脑蛋白（cereblon）领域的深厚投资积淀，也体现了我们在靶向蛋白降解科学领域推动创新的实力，从而打造出一个独具特色的引擎，以催生新的药物发现机会。迄今为止，这项新技术已展现出在四个月内针对高价值靶点提供具有吸引力的先导化合物的能力，并进一步提升了我们药物发现工作的速度与精准度。”

We are eager to push the boundaries of this library and our rapid screening process with diverse and undruggable targets both for our own internal pipeline and alongside future partners.”.

我们渴望突破该库及快速筛选流程的边界，面向多样且难以成药的靶点，既服务于我们自身的内部研发管线，也与未来合作伙伴协同推进。

Integrated within C4T’s TORPEDO

集成于 C4T 的 TORPEDO 系统中

®

®

platform, the addition of DEL creates a powerful hit-finding engine that enables the rapid development of targeted protein degraders. C4T has integrated the company’s cereblon-binding ligand libraries into its DEL capability, which has helped develop a diverse library unique to C4T. The target-first approach integrated into C4T’s DEL technology further enables rapid evaluation, validation, characterization and development of molecular glue degraders..

在该平台上，DNA编码库（DEL）的引入构建了一个强大的先导化合物发现引擎，能够加速靶向蛋白降解剂的开发。C4T 已将其 cereblon 结合配体库整合到 DEL 技术平台中，从而建立起一个独具特色且多样化的 C4T 专属化合物库。C4T 的 DEL 技术所融合的“靶点优先”策略，进一步实现了对分子胶降解剂的快速评估、验证、表征和开发。

C4T has validated this DEL capability by identifying both known and novel molecular glue degrader hits for VAV1, which C4T does not plan to advance without a partner. Led by its target-first approach, C4T has also screened a range of high-value targets where degradation turns undruggable to druggable or provides a therapeutic benefit relative to inhibitors; this has identified hits for additional undisclosed targets.

C4T 通过鉴定出针对 VAV1 的已知和新型分子胶降解剂候选化合物，验证了其 DEL 平台的能力；若无合作伙伴，C4T 不计划推进这些候选化合物的进一步开发。在以靶点为先导的策略推动下，C4T 还对一系列高价值靶点进行了筛选，在这些靶点中，降解作用能够将“不可成药”转化为“可成药”，或相较于抑制剂提供治疗优势；该筛选已发现针对其他未公开靶点的候选化合物。

C4T remains focused on advancing cemsidomide through clinical development and its discovery strategy centered around undisclosed targets that drive inflammation, neuroinflammation and neurodegenerative diseases..

C4T 仍专注于推进 cemsidomide 的临床开发，并实施以未公开靶点为核心的发现策略，这些靶点驱动炎症、神经炎症和神经退行性疾病。

C4T will highlight this new capability and more information on the VAV1 target in a presentation at the 9

C4T将在第9届会议上通过演讲重点介绍这一新功能以及关于VAV1靶点的更多信息

th

泰国

Annual Targeted Protein Degradation Summit on October 29, 2026. The presentation is available on C4T’s

2026年10月29日举行的年度靶向蛋白降解峰会。演讲资料可在C4T上获取。

website

网站

, under Scientific Presentations and Publications.

，在科学报告与出版物部分。

About the TORPEDO

关于TORPEDO

®

®

Platform

平台

The proprietary TORPEDO

专有技术 TORPEDO

®

®

platform drives C4 Therapeutics’ (C4T) efforts to create a new generation of small molecule medicines centered around heterobivalent degraders (BiDAC

该平台推动了C4 Therapeutics（C4T）致力于开发以异双价降解剂（BiDAC）为中心的新一代小分子药物

™

商标

degraders), molecular glue degraders (MonoDAC

降解剂），分子胶降解剂（MonoDAC

®

®

degraders) and degrader-antibody conjugates (DACs). A DNA-encoded library (DEL) that leverages C4T’s cereblon binder library alongside machine learning and artificial intelligence serves as a rapid hit-finding engine. Once a hit is identified, the TORPEDO platform utilizes diverse chemical libraries, degrader design assisted by structural biology, ternary complex models and proteomics, allowing C4T’s scientists to rapidly design degraders with properties that enhance catalytic degradation turnover and drug performance that directly impact disease..

降解剂）以及降解剂-抗体偶联物（DACs）。一种DNA编码库（DEL）利用C4T的cereblon结合剂库，并结合机器学习和人工智能，作为快速发现先导化合物的引擎。一旦确定先导化合物，TORPEDO平台便利用多样化的化学库、结构生物学辅助的降解剂设计、三元复合物模型以及蛋白质组学技术，使C4T的科学家能够快速设计出具有增强催化降解周转率和药物性能的降解剂，从而直接对疾病产生影响。

About C4 Therapeutics

关于 C4 Therapeutics

C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO.

C4 Therapeutics（C4T）（纳斯达克股票代码：CCCC）是一家处于临床阶段的生物制药公司，致力于实现靶向蛋白降解科学的潜力，打造变革患者生活的新一代药物。C4T 正通过临床研究推进其靶向肿瘤学项目，并利用其 TORPEDO 技术平台。

®

®

platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes.

平台，用于高效设计和优化小分子药物，以应对难治性疾病。C4T的降解剂药物旨在利用人体天然的蛋白质回收系统，快速降解致病蛋白，从而有望克服耐药性、攻克不可成药靶点并改善患者预后。

For more information, please visit .

更多信息，请访问。

www.c4therapeutics.com

www.c4therapeutics.com

.

。

Forward Looking Statement

前瞻性陈述

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to discover or develop potential therapies for patients; the capabilities and potential benefits of our DEL and its ability to accelerate drug discovery; the capabilities of the TORPEDO.

本新闻稿包含经1995年《私人证券诉讼改革法案》界定的“前瞻性陈述”。这些前瞻性陈述可能包括但不限于，关于我们为患者发现或开发潜在疗法的能力、我们的DEL（DNA编码库）的能力及其加速药物发现的潜力和益处、以及TORPEDO的能力的明示或暗示性陈述。

®

®

platform; the advancement, timing, progress and potential benefits of our discovery and clinical programs, including cemsidomide; the potential for future collaborations, partnerships, milestone or royalty payments; and our ability to fund its future operations. Any forward-looking statements in this press release are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.

平台；我们包括cemsidomide在内的发现和临床项目的进展、时间安排、进度及潜在益处；未来合作、伙伴关系、里程碑付款或特许权使用费支付的潜力；以及我们为未来运营提供资金的能力。本新闻稿中的任何前瞻性陈述均基于管理层当前的预期和假设，并受风险和不确定性的影响，这些风险和不确定性可能导致实际结果与上述前瞻性陈述中所述或暗示的结果产生重大且不利的差异。

These risks and uncertainties include, but are not limited to: risks inherent in drug discovery and development; the risk that screening results or identified hits may not be reproducible, validated or successfully translated into product candidates; the risk that the results of preclinical studies and/or clinical trials will not be predictive of results from future studies or trials; the timing and outcome of regulatory submissions or interactions; and the risk that any one or more of our programs or product candidates will cost more to develop or may not be successfully developed and commercialized.

这些风险和不确定性包括但不限于：药物发现和开发中固有的风险；筛选结果或已识别的命中化合物可能无法重现、验证或成功转化为候选产品的风险；临床前研究和/或临床试验的结果可能无法预测未来研究或试验结果的风险；监管申报或互动的时间和结果的不确定性；以及我们的任何一项或多项计划或候选产品开发成本可能超出预期，或可能无法成功开发并商业化的风险。

For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission.

有关这些及其他风险与不确定性，以及其他重要因素的讨论（任何此类因素均可能导致我们的实际结果与前瞻性陈述中所载内容存在差异），请参阅 C4 Therapeutics 向美国证券交易委员会提交的最新 Form 10-K 年度报告和/或 Form 10-Q 季度报告中标题为“风险因素”的章节。

All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law..

本新闻稿中的所有信息均截至发布之日，除非法律另有要求，C4 Therapeutics 不承担更新该信息的义务。

Contacts:

联系人：

Investors:

投资者：

Courtney Solberg

考特尼·索尔伯格

Associate Director, Investor Relations

投资者关系副总监

CSolberg@c4therapeutics.com

CSolberg@c4therapeutics.com

Media:

媒体：

Loraine Spreen

洛雷恩·斯普林

Senior Director, Corporate Communications & Patient Advocacy

企业传播与患者倡导高级总监

LSpreen@c4therapeutics.com

LSpreen@c4therapeutics.com